↓ Skip to main content

Dove Medical Press

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy

Overview of attention for article published in Drug Design, Development and Therapy, January 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news
1 news outlet
wikipedia
1 Wikipedia page

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
58 Mendeley
Title
Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
Published in
Drug Design, Development and Therapy, January 2017
DOI 10.2147/dddt.s104227
Pubmed ID
Authors

Ádám Annus, László Vécsei

Abstract

Parkinson's disease (PD) is a progressive, chronic, neurodegenerative disease characterized by rigidity, tremor, bradykinesia and postural instability secondary to dopaminergic deficit in the nigrostriatal system. Currently, disease-modifying therapies are not available, and levodopa (LD) treatment remains the gold standard for controlling motor and nonmotor symptoms of the disease. LD is extensively and rapidly metabolized by peripheral enzymes, namely, aromatic amino acid decarboxylase and catechol-O-methyltransferase (COMT). To increase the bioavailability of LD, COMT inhibitors are frequently used in clinical settings. Opicapone is a novel COMT inhibitor that has been recently approved by the European Medicines Agency as an adjunctive therapy to combinations of LD and aromatic amino acid decarboxylase inhibitor in adult PD patients with end-of-dose motor fluctuations. We aimed to review the biochemical properties of opicapone, summarize its preclinical and clinical trials and discuss its future potential role in the treatment of PD.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 58 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 19%
Student > Bachelor 11 19%
Student > Ph. D. Student 4 7%
Student > Postgraduate 3 5%
Student > Doctoral Student 2 3%
Other 9 16%
Unknown 18 31%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 9 16%
Medicine and Dentistry 7 12%
Biochemistry, Genetics and Molecular Biology 6 10%
Agricultural and Biological Sciences 4 7%
Neuroscience 4 7%
Other 6 10%
Unknown 22 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2017.
All research outputs
#2,962,196
of 22,950,943 outputs
Outputs from Drug Design, Development and Therapy
#158
of 2,096 outputs
Outputs of similar age
#62,228
of 420,989 outputs
Outputs of similar age from Drug Design, Development and Therapy
#6
of 32 outputs
Altmetric has tracked 22,950,943 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,096 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,989 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.